Abstract

EE64 Treatment-Related Costs of Ponatinib and Asciminib in Adults Patients with T315I-Positive Chronic Phase Chronic Myeloid Leukemia with Resistance or Intolerance to at Least Two Prior Kinase Inhibitors in the United States

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.